Imunon

What Imunon does

Imunon is a public, clinical-stage biotechnology company developing non-viral DNA therapies and vaccines. Its lead candidate, IMNN-001, uses the TheraPlas modality to encode IL-12 and interferon gamma, producing cancer-fighting proteins locally at ovarian tumor sites; in Phase 2 it was combined with standard chemotherapy in women with newly diagnosed advanced ovarian cancer, and it is now in the pivotal Phase 3 OVATION 3 trial. The broader technology base includes TheraPlas for protein and cytokine coding in solid tumors and PlaCCine for coding viral antigens in vaccines.

Imunon is pre-revenue and has no approved products or publicly disclosed pricing. It expects its commercial path to depend on successful IMNN-001 development and a future BLA filing, while PlaCCine is positioned for partnerships that could generate licensing royalties or milestone payments. Its current go-to-market activity is therefore clinical and stakeholder development—advancing the lead trial, generating translational evidence, and engaging regulators, investigators, investors, and potential pharmaceutical partners—rather than product sales. Primary.

Name

Imunon

Legal name

IMUNON, Inc.

Website

https://imunon.com

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

11–50 employees

Short description

Imunon is a clinical-stage biotechnology company developing non-viral DNA immunotherapies and vaccines, led by IMNN-001 for patients with newly diagnosed advanced ovarian cancer and PlaCCine-based vaccine candidates. Its lead program is in Phase 3 development.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• DNA immunotherapy
• Ovarian cancer treatment
• Non-viral gene therapy
• DNA vaccine platform
• Clinical stage biopharmaceutical

Headquarters

HQ city

Lawrenceville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. IMNN-001 Commercialization: Pre-revenue. IMUNON is a clinical-stage biotechnology company with no approved products. The company intends to generate revenue through the potential future commercialization of its DNA-based immunotherapy IMNN-001 following FDA approval. The OVATION 3 Phase 3 trial, if successful, is intended to support a Biologics License Application (BLA) filing with the FDA.
2. PlaCCine Platform Licensing/Partnerships: The company is actively seeking strategic partnerships with pharmaceutical and biotechnology companies to accelerate development and commercialization of the PlaCCine DNA vaccine platform, which may generate licensing royalties or milestone payments in the future.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Imunon is a clinical-stage biotechnology company developing DNA-based immunotherapies and vaccines using proprietary non-viral DNA technology platforms. Its lead clinical candidate IMNN-001 is a TheraPlas-based IL-12 DNA immunotherapy currently in a pivotal Phase 3 trial (OVATION 3) for newly diagnosed advanced ovarian cancer. The company also develops the PlaCCine DNA vaccine platform (with IMNN-101 as a completed Phase 1 COVID-19 booster candidate) and is pursuing pharmaceutical partnerships for vaccine and oncology applications.

Product overview

Imunon is a clinical-stage biotechnology company developing a portfolio of DNA-based immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer currently in Phase 3 trials (OVATION 3). The technology portfolio consists of two distinct modalities: TheraPlas, used for coding proteins and cytokines for solid tumor treatment (supporting IMNN-001), and PlaCCine, used for coding viral antigens for vaccine development (supporting IMNN-101 and cancer vaccine programs). The company operates with a focused pipeline approach, advancing its lead immunotherapy candidate through late-stage clinical development while leveraging its DNA technology platforms for additional therapeutic applications.

Differentiator

Problem solved

Functional benefit

Brands

• TheraPlas: DNA technology modality developed for coding proteins and cytokines in the treatment of solid tumors where an immunological approach is promising
• PlaCCine

Products and services

• IMNN-001 DNA-based immunotherapy for the localized treatment of advanced (Stage III/IV) ovarian cancer that works by instructing the body to produce cancer-fighting molecules such as interleukin-12 (IL-12) and interferon gamma at the tumor site. Combined with standard-of-care chemotherapy, it demonstrated a 14.7-month median overall survival improvement (45.1 vs 30.4 months) in the Phase 2 OVATION 2 trial. The product has FDA Fast Track and Orphan Drug designations and is intended for women with newly diagnosed advanced ovarian cancer treated in combination with chemotherapy.
• IMNN-101 DNA-based COVID-19 booster vaccine candidate developed using the PlaCCine technology platform. Phase 1 results demonstrated up to a 3-fold median increase in neutralizing antibody titers at six months with better durability than mRNA vaccines after a single dose. The product targets infectious disease vaccine applications and is intended to be advanced through partnerships.

Quantifiable outcome

• Median overall survival improvement of 14.7 months (45.1 vs 30.4 months) with IMNN-001 plus standard chemotherapy vs chemotherapy alone in Phase 2 OVATION 2 trial (112 patients)
• +4 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Break Through CancercoreStrategic or Co-development Partner · 21 July 2025IMUNON is collaborating with Break Through Cancer on a minimal residual disease (MRD) translational clinical study of IMNN-001 in newly diagnosed advanced ovarian cancer. The partnership involves translational research to evaluate MRD positivity rates and ctDNA clearance. Preliminary data from this study showed encouraging results supporting the Phase 2 OVATION 2 findings.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson Cancer Center serves as a lead clinical investigation site for the IMNN-001 MRD study, which is conducted in partnership with Break Through Cancer. Investigators at MD Anderson are leading the translational research component evaluating minimal residual disease and ctDNA clearance in ovarian cancer patients treated with IMNN-001.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Inovio Pharmaceuticals: Inovio develops DNA medicines and vaccines using nucleic-acid delivery platforms, making it a direct technology peer to Imunon's non-viral DNA immunotherapy and vaccine programs. Its delivery methods and clinical pipeline differ, but the core modality and development model are closely aligned.
• OncoSec Medical: OncoSec developed intratumoral plasmid IL-12 immunotherapy, making it a close modality and cancer-immunotherapy comparator to Imunon's TheraPlas IL-12 program. Its late-stage oncology development focus is directly comparable, although the programs target different tumor types.

Broad incumbents

• Moderna: Moderna is a large public nucleic-acid medicines and vaccines company centered on mRNA technology. It is a broad platform and market comparator for Imunon's DNA-based vaccine and immunotherapy assets, but its modality is mRNA rather than non-viral DNA.
• ImmunityBio: ImmunityBio is a broader cancer-immunotherapy company developing cellular, antibody, and vaccine approaches, including immune-based treatments for solid tumors. It is a useful target-market and scale comparator for Imunon's late-stage ovarian-cancer immunotherapy, despite its wider portfolio.
• Bavarian Nordic: Bavarian Nordic is an established vaccine and immunotherapy company with commercial vaccine capabilities and oncology programs. It provides a broad incumbent comparator for Imunon's vaccine platform, regulatory execution, and potential commercialization path.
• BioNTech: BioNTech is a large mRNA immunotherapy and cancer-vaccine company with a strong oncology focus. It is a broad incumbent comparator to Imunon's DNA immunotherapy and vaccine platforms, especially for oncology development and partner-driven value creation.

Emerging players

• Transgene: Transgene develops viral-vector and oncolytic immunotherapy and vaccine candidates for cancer and infectious diseases. It is comparable to Imunon's therapeutic-vaccine and oncology focus, but its delivery technology is not non-viral DNA.
• Genelux: Genelux is a clinical-stage biotechnology company using oncolytic viruses to stimulate anti-tumor immunity. It shares Imunon's immuno-oncology target market and clinical-development profile, but uses a different therapeutic delivery mechanism.
• PDS Biotechnology: PDS Biotechnology develops Versamune, a synthetic immunotherapy platform intended to stimulate antigen-specific immune responses in cancer and infectious disease. It overlaps with Imunon's immunotherapy and vaccine positioning, but uses a different delivery modality.

Regional players

• Genexine: Genexine is a South Korean biotechnology company developing DNA vaccines and immunotherapeutics. It is relevant to Imunon's PlaCCine and TheraPlas platforms, although its primary operating geography and pipeline differ from the U.S.-focused company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/imunon

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds11 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imunon